Jove
Visualize
お問い合わせ

関連する概念動画

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

26
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Clinical and prognostic significance of urinary albumin-to-creatinine ratio in heart failure: insights from the RICA-2 registry.

European journal of internal medicine·2026
Same author

Chronic obstructive pulmonary disease and CA125 levels in ambulatory chronic heart failure: The COPA-HF study.

International journal of cardiology·2026
Same author

Real-world dosing patterns and outcomes of edoxaban in patients with non-valvular atrial fibrillation and type 2 diabetes mellitus: A gender perspective study.

Medicina clinica·2026
Same author

Impact of age on the prognostic benefit of follow-up in UMIPIC units: analysis of the RICA registry.

Internal and emergency medicine·2026
Same author

Serum chloride and the response to hydrochlorothiazide in patients with acute heart failure: a post-hoc analysis from the CLOROTIC trial.

Revista espanola de cardiologia (English ed.)·2026
Same author

Combined Prognostic Value of the PROFUND Index and Serum Albumin for One-Year Mortality in Elderly Patients with Acute Heart Failure.

Journal of clinical medicine·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する実験動画

Updated: Sep 10, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K

心不全および心房細動の患者における総合的なケアモデルの利点:UMIPICプログラム

José Luis García-Klepzig1, Manuel Méndez Bailón2, Manuel Montero-Pérez-Barquero3

  • 1Servicio de Medicina Interna, Hospital Clínico San Carlos, Facultad de Enfermería, Fisioterapia y Podología, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IDISSC), Madrid, España.

Medicina clinica
|August 27, 2025
PubMed
まとめ

UMIPICプログラムは,心不全と心房細動の患者の総合的なケアを提供しており,1年以内に入院と死亡率を大幅に減少させました. この革新的なアプローチは 脳卒中のリスクを高めることなく 患者のアウトカムを改善しました

キーワード:
心房細動耳動心不全心臓不全死亡率死亡率プログラムプログラム再入学レインゲロスUMIPIC

さらに関連する動画

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

872

関連する実験動画

Last Updated: Sep 10, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

872

科学分野:

  • 心臓病科
  • 公衆衛生
  • 医療管理

背景:

  • 心不全 (HF) と心房細動 (AF) の患者は,入院や死亡のリスクが高くなります.
  • これらのリスクに対処するために UMIPICプログラムという 包括的で継続的なケアモデルが導入されました

研究 の 目的:

  • HFとAFの両方の患者の管理におけるUMIPICプログラムの有効性を評価する.
  • この介護モデルの入院,死亡,脳卒中の発生率への影響を評価する.

主な方法:

  • 2008年3月から2020年3月までの期間で実施された前向きな研究で,5644人の患者が対象となり,そのうち3005人がAF歴を有する.
  • 患者は退院後,UMIPICプログラムグループ (1142) または従来のケアグループ (1863) に分けられました.
  • 傾向スコアマッチングは,12ヶ月のアウトカム分析のための比較可能なコホートを作成するために使用されました.

主要な成果:

  • UMIPICグループは,従来のグループと比較して,あらゆる原因による入院率 (35. 6% 対 44. 8%) とHFの入院率 (18. 3% 対 29. 6%) が著しく低下した.
  • UMIPIC群では全死亡率が低下した (23. 2% vs 31%).
  • 二つのグループ間で,不全性脳卒中の発生率の有意な差は認められませんでした.

結論:

  • UMIPICのケアプログラムは,HFとAFの患者の入院と死亡率を効果的に減少させます.
  • 総合的で継続的なケアモデルは リスクの高い患者集団の治療結果を改善できます
  • UMIPICプログラムは好ましいリスク・ベネフィット・プロファイルを示しており, 血性脳卒中率は増加していません.